SL910102
目录号 : GC32591
SL910102是一种非肽类的血管紧张素AT1受体拮抗剂。
Cas No.:144756-71-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Kinase experiment: | For saturation as well as displacement studies, rat lung homogenate is incubated in either Hepes-buffer or blank human or rat plasma yielding 50 μg protein per well in a total assay volume of 300 μL. To ensure equilibrium conditions (see binding kinetics), the samples are maintained for 60 min at 25°C under continuous rotation. All experiments are carried out in duplicate, and the results are confirmed with n=3-5 replicates over the following days[1]. |
References: [1]. Soldner A, et al. A radioreceptor assay for the analysis of AT1-receptor antagonists. Correlation with complementary LC data reveals a potential contribution of active metabolites. J Pharm Biomed Anal. 1998 May;17(1):111-24. | |
SL910102 is a nonpeptide angiotensin AT1 receptor antagonist.
SL910102 (SL 91.0102-90 DL) is a unlabelled nonpeptide AT1-antagonist, which is tested for its ability to compete with [125J](Sar1-Ile8)-angiotensin II for specific AT1-receptor sites in rat lung homogenate[1].
[1]. Soldner A, et al. A radioreceptor assay for the analysis of AT1-receptor antagonists. Correlation with complementary LC data reveals a potential contribution of active metabolites. J Pharm Biomed Anal. 1998 May;17(1):111-24.
| Cas No. | 144756-71-8 | SDF | |
| Canonical SMILES | O=C1N=C(CCC2=CC=CC=C2)NC(CCCC)=C1CC3=CC=C(C4=CC=CC=C4C5=NN=NN5)C=C3 | ||
| 分子式 | C30H30N6O | 分子量 | 490.6 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0383 mL | 10.1916 mL | 20.3832 mL |
| 5 mM | 0.4077 mL | 2.0383 mL | 4.0766 mL |
| 10 mM | 0.2038 mL | 1.0192 mL | 2.0383 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。